Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0235
PERSPECTIVE
|
Intratumor heterogeneity and personalized medicine – Resistance to everolimus treatment of renal cancer and new therapeutics. |
Prof. Theodore Liakakos, MD, PhD
|
Affiliation: Theodore Liakakos, MD, Professor of Surgery, 3rd Department of Surgery, University of Athens, School of Medicine, Attikon University Hospital, Rimini 1, Chaidari, Athens 12462, Greece.
E-mail: theodlia@otenet.gr |
Abstract
Applying whole-exome sequencing (WES) not in a single biopsy but in multiple separate biopsies of the same renal cancer, a recent study published in NEJM revealed substantial diversity [1]. This finding may have important diagnostic, prognostic, predictive and therapeutic implication not only for renal cancer treatment but for most cancer types. Perspectives and challenges to reach personalized medicine in routine clinical oncological practice through deeper understanding of genetic and genomic heterogeneity and its impact on gene expression and cellular signaling networks are discussed.
(Citation: Gastric & Breast Cancer 2012; 11(3): 118-120)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
|
